← Back to Home

News and Press

April 4, 2013

Cerulean Pharma to Present Data on CRLX101’s HIF-1α Inhibition at the American Association for Cancer Research Annual Meeting

Read more →

Cerulean’s nanopharmaceuticals can be selectively delivered to inflamed tissue. Nanopharmaceuticals are shown in yellow and inflamed colon is shown in purple and blue.

Press Releases

Apr 4, 2013
Cerulean Pharma to Present Data on CRLX101’s HIF-1α Inhibition at the American Association for Cancer Research Annual Meeting
Mar 22, 2013
Cerulean Announces Results from Phase 2b Lung Cancer Trial
Jan 31, 2013
Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer
Jan 29, 2013
Cerulean Pharma to Present Avastin®-CRLX101 Synergy Data at the 15th International Symposium on Anti-angiogenic Therapy
Jan 7, 2013
CRLX101 Advances to Second Stage of Phase 2 Clinical Trial in Advanced Ovarian Cancer
Jan 3, 2013
Cerulean Announces First Patient Dosed in Phase 2 Pharmacodynamic Study of CRLX101 in Gastric Cancer
Nov 19, 2012
Cerulean Pharma’s Lead Candidate Selected as a “Top 10 Oncology Project to Watch”

View by year:

2013 2012 2011 2010 2009 2008 2007

Featured News

Mar 6, 2013 - Xconomy
Cerulean Pharma Arrives at Turning Point With Cancer Drug
Jan 10, 2013 - Metro
Experimental Ovarian Cancer Drug Moves Forward
Jan 7, 2013 - Fox Business News
Cerulean CEO: The IPO Environment is Very Encouraging
Dec 17, 2012 - Boston Business Journal
Cerulean Pharma Gets $13M Series D Extension
Dec 11, 2012 - Fierce Biotech
Exclusive: Cerulean Hauls In $13M, Revs Up Deal Talks As It Nears Ph 2b Cancer Data
Aug 30, 2012 - Technology Review
Nanoparticles Could Lead to Stronger Drugs, Fewer Side Effects for Cancer Patients
Jul 9, 2012 - Forbes
The Promise of Nano Cancer Drugs

View by year:

2013 2012 2011 2010